Single User License
INR 136040
Site License
INR 272080
Corporate User License
INR 408120

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Varicella Zoster (HHV-3) Infections-Pipeline Review, H1 2015

Varicella Zoster (HHV-3) Infections-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Varicella Zoster (HHV-3) Infections-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Varicella Zoster (HHV-3) Infections-Pipeline Review, H1 2015', provides an overview of the Varicella Zoster (HHV-3) Infections's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Varicella Zoster (HHV-3) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Varicella Zoster (HHV-3) Infections and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Varicella Zoster (HHV-3) Infections

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Varicella Zoster (HHV-3) Infections and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Varicella Zoster (HHV-3) Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Varicella Zoster (HHV-3) Infections pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Varicella Zoster (HHV-3) Infections

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Varicella Zoster (HHV-3) Infections pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Varicella Zoster (HHV-3) Infections Overview 9

Therapeutics Development 10

Pipeline Products for Varicella Zoster (HHV-3) Infections-Overview 10

Pipeline Products for Varicella Zoster (HHV-3) Infections-Comparative Analysis 11

Varicella Zoster (HHV-3) Infections-Therapeutics under Development by Companies 12

Varicella Zoster (HHV-3) Infections-Therapeutics under Investigation by Universities/Institutes 14

Varicella Zoster (HHV-3) Infections-Pipeline Products Glance 15

Late Stage Products 15

Clinical Stage Products 16

Early Stage Products 17

Unknown Stage Products 18

Varicella Zoster (HHV-3) Infections-Products under Development by Companies 19

Varicella Zoster (HHV-3) Infections-Products under Investigation by Universities/Institutes 21

Varicella Zoster (HHV-3) Infections-Companies Involved in Therapeutics Development 22

Astellas Pharma Inc. 22

Beijing Minhai Biotechnology Co., Ltd 23

Beijing Tiantan Biological Products Co., Ltd. 24

China National Pharmaceutical Group Corporation 25

Chongqing Zhifei Biological Products Co., Ltd. 26

Epiphany Biosciences, Inc. 27

Foamix Pharmaceuticals Ltd. 28

GlaxoSmithKline plc 29

Green Cross Corporation 30

Merck & Co., Inc. 31

NAL Pharmaceuticals Ltd. 32

Sinovac Biotech Ltd. 33

SK Chemicals Co., Ltd. 34

Spider Biotech 35

Varicella Zoster (HHV-3) Infections-Therapeutics Assessment 36

Assessment by Monotherapy Products 36

Assessment by Combination Products 37

Assessment by Target 38

Assessment by Mechanism of Action 40

Assessment by Route of Administration 42

Assessment by Molecule Type 44

Drug Profiles 46

acyclovir-Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

amenamevir-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

chickenpox vaccine-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

chickenpox vaccine-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

FV-100-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

GSK-1437173A-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

herpes zoster vaccine-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

HHV-3 vaccine-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

measles + mumps + rubella + varicella vaccine-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

measles + mumps + rubella + varicella vaccine-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

measles + rubella + varicella vaccine-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

MG-1111-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

NAL-3221-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

NAL-3223-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

RKP-00156-Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

sattabacin-Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

SB-105A10-Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

V-212-Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

valomaciclovir stearate-Drug Profile 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

varicella vaccine-Drug Profile 70

Product Description 70

Mechanism of Action 70

R&D Progress 70

varicella vaccine-Drug Profile 71

Product Description 71

Mechanism of Action 71

R&D Progress 71

Varicella Zoster (HHV-3) Infections-Recent Pipeline Updates 72

Varicella Zoster (HHV-3) Infections-Dormant Projects 77

Varicella Zoster (HHV-3) Infections-Discontinued Products 79

Varicella Zoster (HHV-3) Infections-Product Development Milestones 80

Featured News & Press Releases 80

Mar 09, 2015: ContraVir Pharmaceuticals to Initiate Pivotal Phase 3 Study of FV-100 for Prevention of Shingles-Associated PHN 80

Dec 18, 2014: Pivotal phase III study of GSK shingles candidate vaccine meets its primary endpoint 80

Dec 18, 2014: Positive Outcome of Phase 3 Study of GSK Shingles Vaccine Containing Agenus Adjuvant 81

Dec 09, 2014: ContraVir Pharmaceuticals Initiates Pharmacokinetic Study of Lead Antiviral FV-100 for Treating Shingles 81

Oct 16, 2014: ContraVir Pharmaceuticals Selects Pharmaceutical Product Development to Manage Phase 2b Study of Lead Antiviral FV-100 for Treating Shingles 82

Apr 09, 2013: Zoster Vaccine Effective Against Incident Herpes Zoster And Post-herpetic Neuralgia In Older US Population, Cohort Study Finds 82

Jul 18, 2012: Agenus Annnounces Intiation Of Phase III Clinical Trial Of GSK's Herpes Zoster Vaccine Candidate In Immunocompromised Patients 84

Jun 05, 2012: Kaiser Permanente Study Shows GSK's Zoster Lowers Short-Term Risk Of Shingles Recurrence 85

Dec 13, 2010: Inhibitex Reports Promising Top-Line Results From Phase II Shingles Trial With FV-100 86

Oct 15, 2010: Inhibitex Completes Enrollment In Phase II Clinical Trial Of FV-100 In Shingles Patients 87

Appendix 88

Methodology 88

Coverage 88

Secondary Research 88

Primary Research 88

Expert Panel Validation 88

Contact Us 88

Disclaimer 89

List of Tables

Number of Products under Development for Varicella Zoster (HHV-3) Infections, H1 2015 10

Number of Products under Development for Varicella Zoster (HHV-3) Infections-Comparative Analysis, H1 2015 11

Number of Products under Development by Companies, H1 2015 13

Number of Products under Investigation by Universities/Institutes, H1 2015 14

Comparative Analysis by Late Stage Development, H1 2015 15

Comparative Analysis by Clinical Stage Development, H1 2015 16

Comparative Analysis by Early Stage Development, H1 2015 17

Comparative Analysis by Unknown Stage Development, H1 2015 18

Products under Development by Companies, H1 2015 19

Products under Development by Companies, H1 2015 (Contd..1) 20

Products under Investigation by Universities/Institutes, H1 2015 21

Varicella Zoster (HHV-3) Infections-Pipeline by Astellas Pharma Inc., H1 2015 22

Varicella Zoster (HHV-3) Infections-Pipeline by Beijing Minhai Biotechnology Co., Ltd, H1 2015 23

Varicella Zoster (HHV-3) Infections-Pipeline by Beijing Tiantan Biological Products Co., Ltd., H1 2015 24

Varicella Zoster (HHV-3) Infections-Pipeline by China National Pharmaceutical Group Corporation, H1 2015 25

Varicella Zoster (HHV-3) Infections-Pipeline by Chongqing Zhifei Biological Products Co., Ltd., H1 2015 26

Varicella Zoster (HHV-3) Infections-Pipeline by Epiphany Biosciences, Inc., H1 2015 27

Varicella Zoster (HHV-3) Infections-Pipeline by Foamix Pharmaceuticals Ltd., H1 2015 28

Varicella Zoster (HHV-3) Infections-Pipeline by GlaxoSmithKline plc, H1 2015 29

Varicella Zoster (HHV-3) Infections-Pipeline by Green Cross Corporation, H1 2015 30

Varicella Zoster (HHV-3) Infections-Pipeline by Merck & Co., Inc., H1 2015 31

Varicella Zoster (HHV-3) Infections-Pipeline by NAL Pharmaceuticals Ltd., H1 2015 32

Varicella Zoster (HHV-3) Infections-Pipeline by Sinovac Biotech Ltd., H1 2015 33

Varicella Zoster (HHV-3) Infections-Pipeline by SK Chemicals Co., Ltd., H1 2015 34

Varicella Zoster (HHV-3) Infections-Pipeline by Spider Biotech, H1 2015 35

Assessment by Monotherapy Products, H1 2015 36

Assessment by Combination Products, H1 2015 37

Number of Products by Stage and Target, H1 2015 39

Number of Products by Stage and Mechanism of Action, H1 2015 41

Number of Products by Stage and Route of Administration, H1 2015 43

Number of Products by Stage and Molecule Type, H1 2015 45

Varicella Zoster (HHV-3) Infections Therapeutics-Recent Pipeline Updates, H1 2015 72

Varicella Zoster (HHV-3) Infections-Dormant Projects, H1 2015 77

Varicella Zoster (HHV-3) Infections-Dormant Projects (Contd..1), H1 2015 78

Varicella Zoster (HHV-3) Infections-Discontinued Products, H1 2015 79

List of Figures

Number of Products under Development for Varicella Zoster (HHV-3) Infections, H1 2015 10

Number of Products under Development for Varicella Zoster (HHV-3) Infections-Comparative Analysis, H1 2015 11

Number of Products under Development by Companies, H1 2015 12

Comparative Analysis by Clinical Stage Development, H1 2015 16

Comparative Analysis by Early Stage Products, H1 2015 17

Assessment by Monotherapy Products, H1 2015 36

Number of Products by Top 10 Targets, H1 2015 38

Number of Products by Stage and Top 10 Targets, H1 2015 39

Number of Products by Top 10 Mechanism of Actions, H1 2015 40

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 41

Number of Products by Top 10 Routes of Administration, H1 2015 42

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 43

Number of Products by Top 10 Molecule Types, H1 2015 44

Number of Products by Stage and Top 10 Molecule Types, H1 2015 45

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Astellas Pharma Inc.

Beijing Minhai Biotechnology Co., Ltd

Beijing Tiantan Biological Products Co., Ltd.

China National Pharmaceutical Group Corporation

Chongqing Zhifei Biological Products Co., Ltd.

Epiphany Biosciences, Inc.

Foamix Pharmaceuticals Ltd.

GlaxoSmithKline plc

Green Cross Corporation

Merck & Co., Inc.

NAL Pharmaceuticals Ltd.

Sinovac Biotech Ltd.

SK Chemicals Co., Ltd.

Spider Biotech

Varicella Zoster (HHV-3) Infections Therapeutic Products under Development, Key Players in Varicella Zoster (HHV-3) Infections Therapeutics, Varicella Zoster (HHV-3) Infections Pipeline Overview, Varicella Zoster (HHV-3) Infections Pipeline, Varicella Zoster (HHV-3) Infections Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com